Research initiatives within the Biostatistics Center at Massachusetts General Hospital.
PETAL (Prevention and Early Treatment of Acute Lung Injury) Network
The Clinical Trials Network for the Prevention and Early Treatment of Acute Lung Injury (PETAL Network) is a network of 12 Clinical Centers (CC) and 1 Clinical Coordinating Center (CCC) funded by the National Heart, Lung, and Blood Institute (NHLBI) to develop and conduct randomized controlled clinical trials to prevent Acute Respiratory Distress Syndrome (ARDS) or provide early treatment to improve the outcome of patients who have ARDS. The PETAL Network is seeking your input and feedback. Learn more.
Autism Speaks/Autism Treatment Network
The AS ATN is the first bi-national network of hospitals, physicians, researchers, and families at 17 centers across the United States and Canada. We are working together to develop the most effective approach to medical care for children and adolescents affected by autism. The Network’s goal is to provide comprehensive, high-quality care by teams of healthcare professionals who understand autism spectrum disorders and excel at treating associated medical conditions. Learn more.
Postoperative pulmonary complications (PPCs) are a major cause of illness and death for patients undergoing open abdominal surgery. The PRIME-AIR study will test whether an intervention bundle (including individualized ventilator settings during anesthesia, optimized muscle relaxation and reversal, and monitoring incentive spirometry after surgery) will reduce the occurrence and severity of PPCs. The MGH Biostatistics Center leads the Statistics and Data Coordinating Center for PRIME-AIR, providing the methodological and logistical support for the design, data collection, quality control, and analysis of data generated from this study.
Integrative Methods for -Omics Data (iMOD)
The collection of big data in biomedicine promises unprecedented opportunities to elucidate complex disease etiology and inform clinical management strategies. Using biomarker response to inflammatory stress as our model system, our team develops, evaluates and applies new analytic approaches for high-dimensional, repeated measures data. Ultimately, these methods will allow us to derive information from the vast quantities of genomics and biomarker data for personalized, clinical decisions and thus serve as a central component of precision medicine.